ArticleScientific reports2025
Intelligent deep learning model for targeted cancer drug delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circadian genesJournal of Zhejiang University. Science. B · 2025Review
- Computational fluid dynamics modeling and simulation of nanoparticle-tumor interaction: Systematic literature review.Computational and structural biotechnology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology and information communication technology (ICT) are being combined to develop innovative drug delivery systems for targeted sites, such as tumor cells. The particulate targeted drug delivery (PTDD) system involves drugs containing nanoparticles embedded in nanoscale devices (referred to as bio-nanomachines) that can cross vascular barriers, resulting in an increased concentration of the drug in the targeted cell or tumor. An artificial intelligence bio-cyber interface (AIBCI) operates in both forward and reverse directions, enabling the transfer or control of a desired drug dose without affecting healthy cells, facilitated by the Internet of Biological Nano Things (IoBNT). This paper proposes a multi-compartmental model with an AI bio-cyber interface based on molecular communication technology. The proposed model is formulated as a set of multi-differential equations designed to identify molecular communication-based bio-nanomachines, enabling the quantification of drug concentration at the targeted cell. Unlike conventional compartmental models, the present model is designed to connect both the exterior and interior of the human body. The results suggest that the model has the potential to improve the capacity of target cells to respond to therapeutic drugs while reducing adverse effects on healthy cells. The intra-body nanonetwork proposed in the present study proved superior performance in magnetifying the drug concentrations in diseased cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.